Table 1 Patient and tumor characteristics according to 70-gene signature use in 2,043 patients within the indicated area for 70-GS use (all younger than 70 years of age with ER+/HER2-, invasive ductal carcinoma)

From: Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study